GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (LTS:0LKB) » Definitions » E10

Vanda Pharmaceuticals (LTS:0LKB) E10 : $0.44 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Vanda Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.090. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.44 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Vanda Pharmaceuticals's average E10 Growth Rate was 83.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Vanda Pharmaceuticals was 78.80% per year. The lowest was 54.00% per year. And the median was 65.30% per year.

As of today (2024-12-15), Vanda Pharmaceuticals's current stock price is $4.5608. Vanda Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was $0.44. Vanda Pharmaceuticals's Shiller PE Ratio of today is 10.37.

During the past 13 years, the highest Shiller PE Ratio of Vanda Pharmaceuticals was 523.00. The lowest was 10.09. And the median was 30.30.


Vanda Pharmaceuticals E10 Historical Data

The historical data trend for Vanda Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals E10 Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.07 0.03 0.24 0.66

Vanda Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.66 0.94 0.44 0.44

Competitive Comparison of Vanda Pharmaceuticals's E10

For the Biotechnology subindustry, Vanda Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Shiller PE Ratio falls into.



Vanda Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.09/133.0289*133.0289
=-0.090

Current CPI (Sep. 2024) = 133.0289.

Vanda Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 1.770 99.070 2.377
201503 -0.240 99.621 -0.320
201506 -0.130 100.684 -0.172
201509 -0.220 100.392 -0.292
201512 -0.350 99.792 -0.467
201603 -0.290 100.470 -0.384
201606 -0.110 101.688 -0.144
201609 -0.010 101.861 -0.013
201612 -0.010 101.863 -0.013
201703 -0.170 102.862 -0.220
201706 -0.030 103.349 -0.039
201709 -0.100 104.136 -0.128
201712 -0.040 104.011 -0.051
201803 0.060 105.290 0.076
201806 0.090 106.317 0.113
201809 0.130 106.507 0.162
201812 0.190 105.998 0.238
201903 -0.010 107.251 -0.012
201906 0.210 108.070 0.259
201909 1.840 108.329 2.260
201912 0.080 108.420 0.098
202003 0.010 108.902 0.012
202006 0.160 108.767 0.196
202009 0.110 109.815 0.133
202012 0.140 109.897 0.169
202103 0.150 111.754 0.179
202106 0.170 114.631 0.197
202109 0.140 115.734 0.161
202112 0.120 117.630 0.136
202203 -0.110 121.301 -0.121
202206 0.050 125.017 0.053
202209 0.060 125.227 0.064
202212 0.120 125.222 0.127
202303 0.060 127.348 0.063
202306 0.030 128.729 0.031
202309 0.002 129.860 0.002
202312 -0.040 129.419 -0.041
202403 -0.070 131.776 -0.071
202406 -0.080 132.554 -0.080
202409 -0.090 133.029 -0.090

Add all the adjusted EPS together and divide 10 will get our e10.


Vanda Pharmaceuticals  (LTS:0LKB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vanda Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=4.5608/0.44
=10.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Vanda Pharmaceuticals was 523.00. The lowest was 10.09. And the median was 30.30.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Vanda Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals Headlines

No Headlines